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Bone remains the most common site of breast cancer recurrence. The results of population studies, pre-
clinical research and clinical studies in patients with metastatic disease provided a rationale for testing
bone-targeted agents in the adjuvant setting. Despite the initial optimism, results from eight prospec-
tively designed, randomized control studies powered to assess the value of adjuvant bone-targeted
therapy in early breast cancer are conﬂicting. Data have shown that, where beneﬁt exists, it tends to be in
women with a “low estrogen environment”, either through menopause or suppression of ovarian
function. In this manuscript, we review clinical data supporting the hypothesis that estrogen levels may
play a part in explaining the response of patients to bone-targeted agents in the adjuvant setting. The
results presented to date suggest that there may be data supporting a unifying role for estrogen in
adjuvant trials. However, in the absence of any prospective randomized trials in which estrogen data has
been systematically collected we cannot speciﬁcally answer this question. We await the results of the
Oxford overview analysis of individual patient data with interest.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In recent years there has been increasing interest in the role of
bone-targeted agents, such as bisphosphonates (BP) and denosu-
mab, as adjuvant therapies for breast cancer. The results of large
randomized trials with BPs have been variable showing either;
beneﬁt [1–3], no beneﬁt [4–7] or harm [8]. However, subgroup
analyses have consistently shown that, where beneﬁt exists, it is in
women with a “low estrogen environment” either through meno-
pause or suppression of ovarian function. In this manuscript, we
review the link between estrogen and breast cancer risk and the
hypothesis that estrogen levels may in part explain the response of
patients to bone-targeted agents in the adjuvant setting.
2. Estrogen and breast cancer link
The pivotal role of cyclical estrogens in breast cancer risk is well
recognized. This has been shown in epidemiological studies where
risk is related to earlier age at menarche, later age at ﬁrst birth and. This is an open access article und
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).menopause, and parity [9,10]. Breastfeeding is protective and is
theorized to be secondary to increased prolactin secretion and
subsequent suppression of estrogen production [11–13]. Studies on
hormone replacement therapy (HRT) have shown increased risk of
breast cancer while receiving combined estrogen and progester-
one hormone replacement [14,15] and, interestingly, a fall in risk
on discontinuation [15–17]. Obesity has also been shown to
increase breast cancer risk in postmenopausal women, which is
likely due to adipose tissue facilitating the conversion of adrenally
secreted dehydroepiandrosterone (DHEA) into estrogen, leading to
elevated estrogen levels [18].
In addition, several studies note that higher serum levels of
estrogen in postmenopausal women are associated with increased
breast cancer risk [19–23]. A meta-analysis of nine prospective
studies, with data on 2428 predominantly postmenopausal women,
663 with breast cancer, demonstrated a roughly twofold higher risk
of breast cancer in women with higher serum estrogen (2nd–4th
quartiles) compared to those with lower levels (1st quartile) [24].3. Estrogen and bone
The importance of estrogen is maintaining bone health is well
recognized [25,26]. The bone microenvironment is dynamic wither the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(bone resorption) and osteoblasts (bone formation). Osteoclasto-
genesis is tightly regulated by the receptor activator of nuclear
factor kappa B ligand (RANKL), receptor activator of nuclear factor
kappa B (RANK) and osteoprotegerin (OPG) system. RANKL is a
protein synthesized by preosteoblast cells. When these proteins
bind to their receptors (RANK) on osteoclast precursor cells, they
stimulate osteoclast differentiation and activation, resulting in
bone resorption [27,28]. Preosteoblast cells also express OPG, a
soluble decoy receptor that binds to RANKL and blocks the
interaction between RANKL and its receptor RANK, thereby
inhibiting osteoclastogenesis [29,30]. OPG is also known to
induce apoptosis in mature osteoclasts, further limiting bone
resorption [31].
The amount of bone resorption is dependent on the balance
between RANKL and OPG. Many cytokines and hormones are
involved in regulation of the RANKL/RANK/OPG system, including
sex steroids [27,30]. Estrogen is known to inhibit RANKL produc-
tion [27,30], and stimulate the production of OPG [32,33]. Thus,
estrogen deﬁcient states result in increased RANKL production,
which in turn overwhelms the OPG decoy receptors. This results in
greater osteoclastogenesis and excessive bone resorption, which
may eventually lead to reduced bone density. Throughout this
process, growth factors are released into the bone microenviron-
ment, which is hypothesized to result in tumor cell proliferation
and survival [34,35]. Thus, in estrogen deﬁcient states, increased
release of growth factors driven by increased osteoclastic resorp-
tion activity may provide a favorable environment for tumor
growth and progression. As such, bone-targeted therapies such
as BPs that inhibit osteoclast activation, should in theory limit
growth factor release and hence tumor cell proliferation.4. Bisphosphonate use and breast cancer risk
BPs are commonly used in the management of postmenopausal
osteoporosis. They consist of two phosphate groups, which give
them a high afﬁnity to bone. They attach to bone at exposed
calcium hydroxyapatite binding sites, which are most accessible at
sites of bone resorption. During bone turnover, BPs are released
causing inhibition of osteoclast-mediated bone resorption [36,37].
In addition, BPs are known to decrease osteoclast development
and recruitment as well as promote osteoclast apoptosis [38,39].
Through these mechanisms, BPs have shown to both increase bone
mineral density (BMD) and decrease osteoporotic fractures [40–43].
Several studies also suggest that postmenopausal women on
oral BPs for osteoporosis have a reduced risk of breast cancer
incidence [44–46]. In theory, the reduction in osteoclast-
resorption limits growth factor release into the bone microenvir-
onment, which may limit cancer cells from proliferating and
developing into malignant tumors. Furthermore, there are data
which suggest BPs have direct anti-tumor effects [47,48].
A large study, the Woman's Health Initiative (WHI), included
154,768 women, 2816 of whom were taking oral BPs for osteo-
porosis at the time of enrollment. After 7.8 years of follow-up,
multivariate analysis demonstrated a 32% risk reduction (Po0.01)
in the incidence of invasive breast cancer and a 30% reduction
(P¼0.02) in the risk of estrogen receptor (ER) positive breast
cancer in postmenopausal women on oral BPs compared to those
not on BP therapy [44].
Rennert et al. observed similar results in their population-
based, case-control study of 4039 postmenopausal women taking
oral BPs, 1832 who were diagnosed with breast cancer [46]. A 28%
relative risk reduction in the incidence of breast cancer was
observed with the use of BPs for greater than one year. A
signiﬁcantly greater number of breast cancers were ER positiveand were less frequently poorly differentiated tumors. Newcomb
et al.'s population based, case-cohort study (N¼5911) yielded
comparable results [45]. Multivariate analysis demonstrated a
signiﬁcant reduction in the risk of breast cancer with BP use (OR
0.67; 95% CI 0.51–0.89). There was increased beneﬁt with increas-
ing duration of BP therapy. Interestingly, beneﬁt was only
observed in non-obese women (BMIo30 kg/m2).5. Pre-clinical studies
In pre-clinical studies, BPs have shown anti-tumor effects
directly through inhibition of tumor proliferation and induction
of apoptosis, and indirectly, through their ability to inhibit tumor
cell adhesion and invasion of the extra-cellular bone matrix, and
their anti-angiogenic and immunomodulatory effects [48–51]. Pre-
clinical animal studies have demonstrated a reduction in the
development of new bone metastases with preventative and
therapeutic dosing of BPs [52–58], as well as inhibition of the
progression of existing bone metastases with therapeutic dosing
[54,56,58].6. Advance disease clinical trials
In patients with bone metastatic disease, studies have shown
BPs to decrease the incidence of skeletal related events, delay the
onset of these complications, and reduce bone pain [59–61]. There
is also evidence that they may improve overall survival in
subgroups of patients with advanced cancers [62].7. Adjuvant bisphosphonate trials
These studies provided a rationale for testing bone-targeted
agents in the adjuvant setting. Despite the initial optimism, results
from eight large prospective randomized control studies powered
to assess the value of adjuvant bone-targeted therapy in early
breast cancer are conﬂicting (Table 1) [1–8,63]. These studies
results are outlined below. However, subgroup analyses from these
studies have shown that women with a “low estrogen environ-
ment,” either through menopause or suppression of ovarian
function, tend to derive greater beneﬁt from adjuvant BP treat-
ment [64].
7.1. Powles study
Powles et al. were the ﬁrst to show a survival beneﬁt with the
use of adjuvant BP in early breast cancer patients [1]. A total of
1069 women with stages I–III breast cancer were randomized to
either two years of oral clodronate or placebo following surgery,
radiotherapy and adjuvant chemotherapy. Results from this study
showed that patients treated with two years of clodronate had a
41% reduction in the risk of developing bone metastases at ﬁve
years (P¼0.043). Additionally, there was a survival advantage in
the clodronate arm with a 23% risk reduction in death with a
median follow-up of 5.6 years (P¼0.048). These beneﬁts appear to
be limited to postmenopausal patients or those with positive ER
status. Results of subgroup analyses demonstrated a signiﬁcant
reduction in bone metastases at two-years (P¼0.017) and a trend
towards signiﬁcance at ﬁve-years (P¼0.056) in postmenopausal
patients treated with two years of adjuvant clodronate therapy
versus the premenopausal subgroup, which showed no beneﬁt
with clodronate on the risk of bone metastases either at two-years
(P¼0.448) or ﬁve-years (P¼0.334).
Table 1
Summary of adjuvant bisphosphonate studies. Adapted from Clemons M, Russell K, Costa L, Addison CL, with permission [58].




Hormone receptor Menopausal status Trial outcome
Positive Negative Unknown Pre Post Unknown
Powles et al.
[1]
Bisphosphonate Clodronate, 1600 mg
daily orally for 2 yr
530 46% 26% 28% 50% 50% - Positive—reduced incidence of bone
metastases and trend for better OS at
5 yr




Bisphosphonate 4 mg zoledronic acid IV
every 3–4wk for
6 cycles, then every
3–6 m for 5 yr
1681 79% 21% 0.8% 45% 46%† 10% Negative—no differences in OS, DFS at
5 yr - increased invasive-disease-free
survival and OS
in woman postmenopausal at least 5 yr
Placebo No 1678 78% 21% 0.4% 45% 46%† 9%
Paterson
et al. [6]
Bisphosphonate Clodronate, 1600 mg
orally daily for 3 yr
1662 75%# NR NR NR 65%# NR Negative—no differences in OS or DFS
at 8 yr
Placebo Yes 1661 75%# NR NR NR 65%# NR
Gnant et al.
[2]
Bisphosphonate 4 mg zoledronic acid IV
every 6 m for 3 yr
900 94.6% 3.3% 2.1% NR NR - Positive—increased DFS and OS at 8 yr
in
patients 440 yr of age
Placebo No 903 93.3% 3.9% 2.6% NR NR -
Diel et al. [3] Bisphosphonate Clodronate, 1600 mg
daily orally for 2 yr
157 75% 25%* 36% 39% - Positive—increased OS at 8.5 yr
Placebo No 145 71% 20%* 64% 61% -
Kristensen
et al. [4]
Bisphosphonate Pamidronate, 150 mg
orally twice a day for
4 yr
460 14% 60% 26% 67% 33% 0% Negative—no differences in OS, DFS or
incidence of metastases at 5 yr
Placebo No 493 17% 53% 30% 66% 34% 0.2%
Mobus et al.
[7]
Bisphosphonate Ibandronate, 50 mg
daily orally for 2 yr
1873 75%* NR NR 50%# NR NR Negative—no differences in OS or DFS
at 5 yr
Placebo No 998 75%* NR NR 50%# NR NR
Saarto et al.
[8]
Bisphosphonate Clodronate, 1600 mg
orally daily for 3 yr
139 61% 35% 4% 48% 52% - Negative—no signiﬁcant differences in
OS or frequency of metastases at 10 yr -
decreased DFS and increased
extraskeletal metastases in clodronate
group at 10 yr
Placebo No 143 68% 23% 9% 57% 43% -
NR – Not Reported.
n Not originally reported therefore may contain Negative and Unknown categories.
† Originally reported as postmenopausal o5 yr and 45 yr but here is represented as combined for total percentage of post-menopausal patients.
# Values taken from meeting abstract/presentation so need ﬁnal publication to conﬁrm values.
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The AZURE trial, although a negative study overall, did show
beneﬁt with adjuvant BP therapy in women who had been in
menopause for at least ﬁve years [5]. A total of 3360 women were
randomized to either ﬁve years of adjuvant zoledronic acid (ZA) or
control in addition to standard adjuvant treatment. After a median
follow-up of 59 months, no signiﬁcant differences in the DFS or OS
were seen between the ZA and control arms. However, subgroup
analyses did show that women postmenopausal for greater than
ﬁve years, had a superior invasive-disease-free survival (IDFS)
when treated with adjuvant ZA in addition to standard adjuvant
therapy (HR 0.75, 95% CI 0.59–0.96, P¼0.02). The ﬁve-year survival
rate in postmenopausal women was also superior in the ZA arm at
84.6% compared to 78.7% in the control group, with a 26% reduced
risk of death (82 vs. 111 deaths; P¼0.04). A follow-up biomarker
analysis using serum collected and stored on 872 AZURE patients
for use in future translational research showed a trend towards
beneﬁt with the use of ZA in biochemically postmenopausal
women [65]. Women with an estradiol level o50 pmol/l had a
21% risk reduction in time to distant recurrence compared to a 56%
increased risk in women with estradiol levels ≥50 pmol/l
(P¼0.056). These results further substantiate the theory that
beneﬁts from BPs are dependent on a “low estrogen environment”.
7.3. NSABP B-34
Similar to the AZURE trial, data from the National Surgical
Adjuvant Breast and Bowel Project protocol B-34 (NSABP-34) demon-
strated superior beneﬁt with adjuvant BP in the postmenopausalpatient population [6]. Over three thousand patients with operable,
stages I–III breast cancer were randomized to three years of oral
clodronate or placebo. With a median follow-up of 90.7 months, no
differences were seen between the groups for DFS, OS, recurrence-
free interval or bone metastasis-free interval. A 26% (P¼0.047)
increase in the non-bone metastasis-free interval was seen in the
clodronate group compared to placebo. Although beneﬁt with
adjuvant BP therapy was limited to NBMFI, subgroup analyses
showed women 50 years or older treated with adjuvant BP therapy
had superior recurrence-free interval (P¼0.045), bone metastasis-
free interval (P¼0.027) and non-bone metastasis-free interval
(P¼0.014) compared to placebo which, similar to other studies,
suggests greater derived beneﬁt from BPs in “low estrogen states”.
7.4. ABCSG-12
Beneﬁt of adjuvant BPs in a “low estrogen” patient population
was also demonstrated in the Austrian Breast and Colorectal
Cancer Study Group trial-12 (ABCSG-12) [2]. This large rando-
mized, open-label, two-by-two factorial trial enrolled 1803 pre-
menopausal women with early stage (stage I–II), ER and/or PR
positive breast cancers. All patients were treated with goserelin, a
luteinizing hormone releasing hormone (LHRH) agonist, with the
intent of achieving castrate estrogen levels. They were then
randomized to receive either tamoxifen or anastrozole with or
without ZA for three years. After a 62-month follow-up, a 32%
improvement in DFS (P¼0.009) was observed in patients treated
with ZA in addition to adjuvant hormonal therapy compared to
adjuvant tamoxifen or anastrozole alone. No difference was seen
in overall survival (OS).
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Diel et al. demonstrated beneﬁt with adjuvant BP treatment [3].
In this trial, 302 women with operable breast cancer who had
evidence of disseminated tumor cells on bone marrow aspirate
and hence were at high risk of relapse were enrolled and
randomized to adjuvant clodronate or to the control arm. After
36 months of follow-up, there was a signiﬁcant reduction in the
incidence of distant metastases, bone metastases, visceral metas-
tases, as well as a signiﬁcant survival advantage in patients treated
with adjuvant BP therapy. At the 103 month follow-up, beneﬁt was
limited to improved OS with a 20.3% reduction in mortality
(P¼0.049) in the BP arm. Although no subgroup analyses to
evaluate pre- versus post-menopausal status were performed,
the majority of patient enrolled were postmenopausal (61–64%).
7.6. KRISTENSEN study
In contrast, no beneﬁt from adjuvant BP therapy was observed
by Kristensen et al. in which 953 women with node negative,
operable breast cancer were randomized to four years of oral
pamidronate or control after surgery, adjuvant chemotherapy, +/
radiotherapy [4]. Interestingly, adjuvant hormonal therapy was
avoided in this trial. Both pre- and postmenopausal women were
enrolled; however ER positive, post-menopausal women were
excluded from the study. Postmenopausal women accounted for
approximately one third of patients in both groups. After ten years
of follow-up, there were no differences in incidence of bone
metastases or OS between groups.
7.7. GAIN study
Similarly, the phase III, German Adjuvant Intergroup Node
Positive (GAIN) study failed to show any survival advantage with
adjuvant BPs, even subgroup analyses of the postmenopausal
population. In this trial, 3023 node positive, breast cancer patients
were initially randomized to intense dose-dense epirubicin, pacli-
taxel and cyclophosphamide (iddETC) or conventionally dosed
epirubicin and paclitaxel (ET) [7]. Patients then underwent a
second randomization to two years of adjuvant ibandronate or
control. Approximately 52% of patients were postmenopausal.
Results from this study failed to show beneﬁt from adjuvant BPs.
No signiﬁcant differences between the ibandronate and observa-
tion groups were evident in the three-year DFS or OS. Subgroup
analyses failed to show any beneﬁt in three-year DFS with
adjuvant BP treatment in the postmenopausal cohort (P¼0.462).
These results suggest that the efﬁcacy of adjuvant BPs may be
dependent on more than just a “low estrogen environment,” or
that different BPs are differentially affected by low estrogen.
7.8. SAARTO study
Saarto et al.'s trial was the only one to demonstrate harmful
effects with adjuvant BP treatment [8]. This study enrolled 299
women with axillary node positive breast cancer and randomized
them to either oral adjuvant clodronate for three years or control.
Premenopausal women were treated with chemotherapy, whereas
postmenopausal women were treated with adjuvant hormonal
therapy with tamoxifen or toremifene. Baseline characteristics
revealed a greater proportion of ER positive patients in the control
group at 68% compared to 61% in the clodronate group, as well as
fewer postmenopausal patients in the control arm (43%) versus
the clodronate arm (52%). At ten-year follow-up, there was no
signiﬁcant difference in bone metastases between treatment arms,
however those treated with BPs were found to do worse with
increased extra-skeletal metastases and a reduced DFS. Extra-skeletal metastases were signiﬁcantly higher in the treatment
cohort (P¼0.004), with 50% of patients on clodronate therapy
developing local or visceral recurrence compared to only 36% of
the control patients.
Ten-year DFS was also signiﬁcantly lower in the clodronate arm
(50%) versus patients in the control arm (64%; P¼0.004). Subgroup
analyses interestingly demonstrated that postmenopausal, ER
positive women were the only subgroup not to have a negative
effect from three years of adjuvant clodronate therapy, again
raising the question of the importance of the patient's “estrogen
environment.” All other subgroups including ER positive and
negative premenopausal patients and ER negative postmenopau-
sal patients did worse when treated with adjuvant clodronate. It is
unclear whether the imbalance in ER status and menopausal
status between the treatment and control arms played a role in
the ﬁnal results. Furthermore, treatment varied between preme-
nopausal (adjuvant chemotherapy) and post-menopausal patients
(adjuvant hormonal therapy), which may have also impacted these
ﬁndings [66–68].8. Predictors of beneﬁt from bisphosphonates
Randomized control studies of adjuvant BP therapy in early
breast cancer show beneﬁt related to “low estrogen states”
[1,2,5,6]. Unfortunately, thus far, only one study has assessed
systemic estrogen levels to substantiate these results. This is
clearly going to remain an issue as accurate assays for estradiol
measurement in postmenopausal women [69–71] and women on
aromatase inhibitors in particular are not widely available [72]. We
therefore have to explore the literature for evidence to support
this hypothesis. It is known that postmenopausal women go
through two phases of bone loss: an initial accelerated phase in
early menopause, followed by a more gradual, continuous phase
[26]. The greatest loss of bone mineral density (BMD) has been
shown to occur within the ﬁrst ﬁve years of menopause during the
early phase, when estrogen levels dramatically decline compared
to premenopausal levels [73,74]. Bone turnover markers are high-
est in perimenopausal women and signiﬁcantly decrease with
increasing age [75]. This suggests that early postmenopausal
women would be at the highest risk of breast cancer recurrence
to the bone during this period given the rate of bone turnover and
increased release of growth factors, creating a fertile environment
for tumor growth. Contrary to expectations, subgroup analysis
from the AZURE trial only showed a signiﬁcant improvement in
IDFS and OS at 5-years in women treated with adjuvant zolen-
dronic acid who where postmenopausal for ﬁve years or more
compared to the control arm. This suggests that the beneﬁt of
adjuvant BPs in early breast cancer patients may depend on more
than simply a “low estrogen environment”.9. Biomarker studies
Studies on predictive markers for developing bonemetastases have
been done to identify those early breast cancer patients at highest risk
for disease recurrence [76–78]. The bone microenvironment is con-
stantly in ﬂux through continuous resorption and formation (bone
turnover). This process releases bone turnover markers (BTM) into the
serum, such as C-terminal telopeptide (CTx), which can be measured
giving an estimate of the rate of bone turnover [79]. Growth factors
are also mobilized through this process, which is hypothesized to
provide a favorable environment for tumor cells to proliferate [34,35].
In theory, elevated levels of BTMs may predict the risk of early breast
cancer patients developing bone metastases and would be clinically
useful.
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question. Pre-treatment serum CTx concentrations were collected
from 621 primary breast cancer patients who were treated with
adjuvant tamoxifen with or without octreotide with the aim of
testing the ability of this marker at predicting disease recurrence
[78]. After a median 7.9 years of follow-up, 123 of 621 (19.8%)
patients developed breast cancer recurrence and of those, 19 had
isolated bone metastases. Analysis of patients with bone-only
disease showed a signiﬁcantly shorter recurrence-free survival
(RFS) in those with elevated pretreatment serum CTx concentra-
tions. This suggests that increased bone turnover provides a
favorable environment for breast cancer and that CTx may be a
good predictive marker for developing bone metastases in patients
with early breast cancer.
Recent research has explored the utility of the BTMs procolla-
gen type I N-terminal propeptide (P1NP), osteocalcin, IL-6 and CTx,
as markers to predict bone metastases in stage I-III breast cancer
patients [76]. This study showed that elevated serum P1NP levels
(≥75 ng/ml) predicted a 2.7 fold increase in the risk of bone
metastases (P¼0.031) and a signiﬁcant decrease in OS (P¼0.031)
in this patient population. CTx surprisingly did not demonstrate
any correlation with bone metastases despite the MA.14 results
[78] and other studies showing elevated CTx levels in patients
with bone metastases [77,80].
In contrast, data from a follow-up biomarker analysis from the
AZURE trial presented at the 2012 San Antonio Breast Cancer
Symposium showed that vitamin D levels and not BTMs predict
risk of breast cancer relapse in women with early breast cancer
[65]. In the study, patient with high baseline levels of 25-OH
vitamin D (30 ng/ml) had a signiﬁcantly lower risk of developing
bone metastases (HR 0.11; P¼0.0257). Both P1NP and CTx levels
however, failed to demonstrate any association with bone relapse.
These ﬁndings demonstrate that predicting risk of breast cancer
recurrence is clearly complex and a single predictor marker may
not be an effective strategy.
Further complicating matters is that although menopause can
increase serum BTMs, other normal physiological conditions,
certain disease states, and drugs are also associated with elevated
BTM concentrations [81–83]. Low body-mass index (BMI) is a risk
factor for low bone density [84] and evidence has shown that
women with low BMIs have higher BTM levels consistent with
elevated bone resorption under these conditions [82]. Alcoholism
and smoking are also associated with elevated BTMs [81,82]. There
is a diurnal variation in bone turnover too, with peak rates of
turnover in the early morning with subsequent elevated serum
BTMs at these times [83].10. Conclusion
Overall, despite extensive pre-clinical and clinical rationale for
the beneﬁts of adjuvant bone-targeted therapies, the results of the
adjuvant trials have not met expectations. Indeed, the multiple
deﬁciencies of the animal models used in this setting have led
authors to question their validity as pre-clinical models for patient
studies [85]. Given the thousands of patients enrolled on these
studies this is clearly disappointing and the results from studies
prospectively designed and powered to show adjuvant beneﬁt on
the whole have been resoundingly negative. Similar to the situa-
tion with any targeted agent such as endocrine therapy or
trastuzumab-based studies, it is important to identify whether or
not a population of patients exists within the main study popula-
tion that might derive greater beneﬁt from the treatment.
Although the data presented to date suggest enhanced beneﬁt in
post-menopausal patients or those with a so called “low estrogen
environment”, deﬁnitive studies supporting this are lacking.Linking bone, adjuvant BPs and the estrogen environment could
lead to the development of a unifying hypothesis to explain the
results of different trials and to help us target appropriate patients
in the future.
In this review we have highlighted data supporting the impor-
tance of estrogen in normal bone physiology. We have looked at
adjuvant BP trials in early breast cancer patients and shown that
one study and subgroup analyses from three other trials demon-
strate a beneﬁt of adjuvant BP in postmenopausal women as well
as one trial showing harm in premenopausal and ER negative
postmenopausal women. Trying to link estrogen and cancer
treatment is however complex in the absence of prospectively
collected serum estrogen levels.
Unfortunately, no randomized control studies in this popula-
tion are currently planned, and anticipated results from the
remaining studies SWOG 0307, D-CARE study and NATAN trial
will not be able to formally answer the question of the role of
estrogen in response to adjuvant bone-targeted therapy. While
groups will likely continue to publish meta-analyses of the
published data [64] we eagerly await the results of the Oxford
overview analysis of individual patient data to see if we can tease
out whether estrogen levels play a role in the efﬁcacy of bone-
targeted therapies in adjuvant breast cancer treatment.Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
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